

Effects of the cannabinoid receptor antagonist hemopressin on amyloid- β induced toxicity in mouse Neuro-2a neuroblastoma cells

S. J. Werner, S. W. Martin, A. W. Paterson, N. G. Milton. School of Clinical & Applied Sciences, Leeds Beckett University, Leeds, United Kingdom.

Introduction: Pepcans are a group of peptide based cannabinoids which are haemoglobin derived. They act as cannabinoid (CB) receptor antagonists/agonists and are found throughout the CNS¹. The pepcan hemopressin (Hp) is a nonapeptide antagonist of the CB₁ receptor¹. Studies have suggested that cannabinoid antagonists, such as the synthetic CB₁ antagonist AM251, have memory enhancing activities following brain trauma². The levels of amyloid- β (A β) are elevated during brain trauma and may contribute to tissue damage³. Previous *in vitro* studies have demonstrated the protective properties of CB₁ receptor ligands against A β induced neurotoxicity⁴. The aim of this study was to determine the effects of Hp on A β toxicity.

Method: This study employed MTT cell viability assays to investigate the effects of the peptide CB₁ antagonist Hp, the peptide CB₁ agonist RVD, the lipid CB agonist 2-arachidonoylglycerol (2-AG), the synthetic CB agonist O-2545, the synthetic CB₁ antagonist AM251, the synthetic CB₂ antagonist AM630 plus the synthetic GPR-55 antagonist CID16020046 (10 μ M for each drug), on 10 μ M A β 25-35 induced neurotoxicity in mouse neuroblastoma Neuro-2a (N2a) cells. Data were analyzed by one-way analysis of variance (ANOVA).

Results: Both Hp and 2-AG had a significant protective effect ($P < 0.05$) on A β 25-35 induced neurotoxicity in N2a cells. The RVD, O-2545 and AM251 had no effect on A β 25-35 induced toxicity in N2a cells (Fig 1A). The RVD, AM251, AM630 and CID16020046 had no effect on Hp protection against A β 25-35 induced toxicity in N2a cells (Fig 1B).




Figure 1. (A) Effect of A β 25-35 plus Hp, RVD, 2-AG, O-2545 or AM251 on MTT reduction in N2a cells. (B) Effect of A β 25-35 with Hp alone or plus RVD, AM251, AM630 or CID16020046 on MTT reduction in N2a cells. Results are mean \pm SEM ($n=8$ for each data point); * = $P < 0.05$ vs control; † = $P < 0.05$ vs A β 25-35 alone; (one-way ANOVA).

Conclusion: In conclusion, the cannabinoid antagonist Hp is protective against A β 25-35 induced neurotoxicity in N2a cells. The Hp protection is not antagonised by RVD or the CB₁, CB₂ or GRP-55 antagonists suggesting either an action via a non-cannabinoid receptor or that Hp is acting allosterically at an alternate binding site within a CB receptor.

References:

- (1) Gomes I *et al.* (2009). *FASEB J.* **23**: 3020-3029.
- (2) Sunada H *et al.* (2017). *J Exp Biol.* **220**:3026-3038.
- (3) Edwards G *et al.* (2017). *Biochem Biophys Res Commun.* **483**: 1137-1142.
- (4) Milton NGN (2002). *Neurosci Letts* **332**: 127-130.